Manocchio Nicola, Ljoka Concetta, Piacentini Nicolò, Sorge Roberto, Vita Giulia, Foti Calogero
Physical and Rehabilitation Medicine, Clinical Sciences and Translational Medicine Department, University of Rome Tor Vergata.
Physical and Rehabilitation Medicine, Clinical Sciences and Translational Medicine Department, University of Rome Tor Vergata, Italy; Physical and Rehabilitation Medicine Unit, Tor Vergata University Hospital, Rome.
Eur J Transl Myol. 2024 Aug 22;34(3):12413. doi: 10.4081/ejtm.2024.12413.
Osteoarthritis (OA) is a disabling disease that causes pain and functional limitation. OA symptoms can be treated with intra-articular injections of anti-inflammatory, viscosupplementary, or viscoinductive products. Non-responders to these approaches have limited options, often surgical (e.g. knee replacement). This retrospective study aims to evaluate the efficacy of a single injection of Carboxymethyl-Chitosan for advanced (Kellgren-Lawrence ≥3) and symptomatic knee OA in non-responders to hyaluronic acid. We enrolled 10 patients (5 female, 5 male). Treatment efficacy was assessed through the Visual Analogue Scale (VAS, pain) and the Knee Injury and Osteoarthritis Outcome Score (KOOS, knee function). Data are acquired from rating scales were administered at the time of injection (T0), one month (T1), three months (T2), and six months (T3) after treatment as for clinical practice. Results showed a significant improvement in pain and function at T1, with a subsequent gradual resumption of symptoms. In conclusion, the treatment showed a better outcome in the short term (i.e. up to 1 month after treatment); however, raw values of VAS and KOOS did not return to baseline levels showing a maintenance of improvement albeit not statistically significant.
骨关节炎（OA）是一种导致疼痛和功能受限的致残性疾病。OA症状可通过关节内注射抗炎、补充粘弹性或诱导粘弹性的产品进行治疗。对这些方法无反应的患者选择有限，通常需要手术治疗（如膝关节置换）。这项回顾性研究旨在评估单次注射羧甲基壳聚糖对晚期（凯尔格伦-劳伦斯分级≥3级）且有症状的膝关节OA患者（对透明质酸无反应者）的疗效。我们招募了10名患者（5名女性，5名男性）。通过视觉模拟评分法（VAS，疼痛）和膝关节损伤与骨关节炎疗效评分（KOOS，膝关节功能）评估治疗效果。按照临床实践，在注射时（T0）、治疗后1个月（T1）、3个月（T2）和6个月（T3）通过评分量表获取数据。结果显示，在T1时疼痛和功能有显著改善，随后症状逐渐恢复。总之，该治疗在短期内（即治疗后1个月内）显示出较好的效果；然而，VAS和KOOS的原始值未恢复到基线水平，虽无统计学意义，但仍维持改善状态。
